Payment overview · 2025
General Payments
$827.16
14 reported records · 5 companies
Healthcare provider profile · identity verified
James E Froelich, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BONHAM, TX · NPI 1649264656
Verified facts
What the public records show
CMS Open Payments records show James E Froelich, D.O. received $827.16 in general payments during 2025 across 14 reported records.
Axsome Therapeutics, Inc. accounted for 46.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $383.95 | 46.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $239.44 | 28.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $176.31 | 21.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.94 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.52 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $827.16 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $383.95 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $239.44 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $176.31 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 493 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 169 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 55 |
| Celecoxib | Celecoxib | 157 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 48 |
| Lisinopril | Lisinopril | 143 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 139 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 31 |
| Potassium Chloride | Potassium Chloride | 126 | 44 |
| Ezetimibe | Ezetimibe | 120 | 29 |
| Omeprazole | Omeprazole | 117 | 30 |
| Gabapentin | Gabapentin | 115 | 33 |
| Metformin Hcl | Metformin Hcl | 114 | 33 |
| Diazepam | Diazepam | 110 | 23 |
| Naproxen | Naproxen | 109 | 34 |
| Ozempic | Semaglutide | 108 | 21 |
| Tramadol Hcl | Tramadol Hcl | 107 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 106 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 29 |
| Furosemide | Furosemide | 101 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 26 |
| Allopurinol | Allopurinol | 89 | 26 |
| Mounjaro | Tirzepatide | 89 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 26 |
| Famotidine | Famotidine | 76 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 21 |
| Pregabalin | Pregabalin | 69 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 23 |
| Jardiance | Empagliflozin | 65 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 63 | 19 |
| Carvedilol | Carvedilol | 60 | 15 |
| Losartan Potassium | Losartan Potassium | 59 | 18 |
| Buspirone Hcl | Buspirone Hcl | 57 | 14 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 16 |
| Terazosin Hcl | Terazosin Hcl | 50 | suppressed |
| Meloxicam | Meloxicam | 47 | 16 |
| Eliquis | Apixaban | 45 | 11 |
| Promethazine Hcl | Promethazine Hcl | 43 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 12 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 36 |
| Montelukast Sodium | Montelukast Sodium | 38 | 11 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 17 |
| Valsartan | Valsartan | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Niacin Er | Niacin | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Prednisone | Prednisone | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $827.16 · 14 records | Axsome Therapeutics, Inc. | Auvelity, CAPLYTA, FREESTYLE LIBRE 3, TRELEGY ELLIPTA, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error